Cargando…
High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4(+) T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens
Multiple myeloma is an incurable disease characterized by unregulated growth of malignant plasma cells in the bone marrow (BM). Tumor-induced dysfunction of T-cells may be responsible for immune evasion and failure of immunotherapy. Therefore, a better understanding of the phenotype of T-cells at th...
Autores principales: | Iversen, Katrine Fladeland, Nederby, Line, Lund, Thomas, Plesner, Torben |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492812/ https://www.ncbi.nlm.nih.gov/pubmed/36131131 http://dx.doi.org/10.1007/s44228-022-00013-7 |
Ejemplares similares
-
Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018) -
Optimizing the Outcome of Anti-Myeloma Treatment with Daratumumab
por: Plesner, Torben
Publicado: (2021) -
The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study
por: Szabo, Agoston Gyula, et al.
Publicado: (2019) -
Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59
por: Brennan, Kieran, et al.
Publicado: (2022) -
P816: PHARMACODYNAMIC ACTIVITY OF GEN3014 (HEXABODY-CD38) IN PATIENTS WITH MULTIPLE MYELOMA SUPPORTS ENHANCED COMPLEMENT DEPENDENT CYTOTOXICITY OF GEN3014 COMPARED TO DARATUMUMAB
por: Hiemstra, Ida H., et al.
Publicado: (2023)